Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $183,465.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $120.29 on Friday. The stock’s 50 day moving average price is $122.55 and its 200 day moving average price is $116.34. The firm has a market cap of $7.27 billion, a P/E ratio of 16.94, a PEG ratio of 0.90 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Jones Financial Companies Lllp grew its holdings in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares in the last quarter. UMB Bank n.a. raised its position in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the last quarter. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares during the last quarter. Finally, Lindbrook Capital LLC grew its stake in Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 176 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.